CureVac up as US court grants request to transfer COVID vaccine patent case

CureVac NV

19/05/2023 15:18

** U.S.-listed shares of German drugmaker CureVac NV
 CVAC.O  up 1.3% at $8.9
    ** CureVac NV filed an expanded patent infringement claim
against Pfizer Inc  PFE.N  and BioNTech  BNTX.O  over the use of
mRNA technology and that a U.S. court had granted its request to
transfer the trial 
    ** Co added it filed a counterclaim alleging that PFE and
partner BNTX infringed on nine of its patents, broader than its
original claim of three patents
    ** In July 2022, CVAC filed a patent lawsuit against BNTX
over the use of mRNA technology in the companies' COVID-19
vaccine 
    ** The transfer of the trial to the Eastern District of
Virginia from the Federal District Court of Massachusetts is
expected to accelerate progress of the case and allow for a
likely 2024 trial date - CureVac 
   ** PFE/BNTX in response had filed a complaint with the U.S.
District Court in Massachusetts, seeking a judgment that they
did not infringe U.S. patents held by CVAV
    ** YTD, CVAC's U.S.-listed stock up ~47% 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))